Diffuse alveolar hemorrhage (DAH) is unusual and can be a life-threatening side effect of glycoprotein IIb/IIIa receptor antagonists like abciximab. Early diagnosis of this condition can play a key role in preventing adverse outcomes. We report a case of a 74-year-old female who suffered from acute lateral wall myocardial infraction and was treated with a coronary angioplasty. She received abciximab infusion during and after coronary angioplasty due to a high thrombus burden. After the procedure, she had worsening respiratory distress with hemoptysis, and on detailed evaluation, DAH secondary to abciximab was diagnosed. The diagnosis of DAH post-myocardial infraction and coronary angioplasty can be challenging as clinically, it can mimic conditions like acute left ventricular failure and pulmonary embolism. A high index of suspicion is required to diagnose DAH secondary to glycoprotein IIb/IIIa receptor antagonist. The treatment is essentially supportive with immediate cessation of the culprit drug and other anticoagulants. Few cases of severe DAH that are refractory to supportive management might benefit from steroids.

弥漫性肺泡出血 (DAH) 并不常见，可能是阿昔单抗等糖蛋白 IIb/IIIa 受体拮抗剂的危及生命的副作用。这种情况的早期诊断可以在预防不良后果方面发挥关键作用。我们报告一例 74 岁女性患者，患有急性外侧壁心肌梗死，并接受冠状动脉血管成形术治疗。由于血栓负荷高，她在冠状动脉血管成形术期间和之后接受了阿昔单抗输注。手术后，她的呼吸窘迫恶化并伴有咯血，经过详细评估，诊断出阿昔单抗继发的 DAH。心肌梗死后 DAH 和冠状动脉成形术的诊断可能具有挑战性，因为在临床上，它可以模仿急性左心室衰竭和肺栓塞等情况。诊断继发于糖蛋白 IIb/IIIa 受体拮抗剂的 DAH 需要高度怀疑。治疗本质上是支持性的，立即停止致病药物和其他抗凝剂。少数对支持性治疗无效的严重 DAH 病例可能会从类固醇中受益。